In CCA, cordycepin can inhibit SREBP1-mediated FA synthesis and exert oncogenic effects by suppressing the AKT/mTOR signaling pathway through the inhibition of ERO1A [139]. Here, AKT1 is linked to cholangiocarcinoma.